文献速递糖尿病

2型糖尿病患者ITGA1水平升高:对心功能损害的意义

Elevated ITGA1 levels in type 2 diabetes: implications for cardiac function impairment.
PubMed 文献 · Diabetologia · 2024-02-27

研究比较伴与不伴射血分数保留的心力衰竭(HFpEF)的2型糖尿病患者血浆整合素α1(ITGA1)水平,并随访中位30个月。结果显示HFpEF患者ITGA1显著升高,与左室重构、舒张功能受损及心脏结构功能恶化独立相关;基线ITGA1独立预测再住院风险(HR 2.331)。

要点

  • 2型糖尿病合并HFpEF者血浆ITGA1水平显著高于不合并HFpEF者。
  • 升高的ITGA1与左室重构和舒张功能受损相关。
  • 基线ITGA1独立预测再住院风险(HR 2.331,95%CI 1.387-3.917,p=0.001)。

核心结论

  • ITGA1可作为监测心脏结构和功能损伤的生物标志物,用于诊断HFpEF的存在,并预测2型糖尿病患者心脏结构功能恶化和再住院风险。

研究设计与样本

  • 研究采集伴与不伴HFpEF的2型糖尿病患者血样进行蛋白质组学分析,比较两组血浆ITGA1水平。
  • 参与者按ITGA1水平分组,在基线和随访中位30个月时接受经胸超声心动图检查。
  • 采用多变量线性和Cox回归分析评估ITGA1与超声心动图指标变化及再住院风险的关联。
  • 分析ProteomeXchange数据库中患者左心室蛋白质组数据以探索ITGA1水平变化的机制。

主要发现

  • 2型糖尿病合并HFpEF者血浆ITGA1水平显著高于不合并HFpEF者。
  • 升高的ITGA1水平与左室重构和舒张功能受损相关。
  • 中位随访30个月的多变量分析显示,升高的ITGA1水平独立 correlated with 舒张和收缩心脏功能的恶化。
  • 较高的基线血浆ITGA1水平独立预测再住院风险(HR 2.331,95%CI 1.387-3.917,p=0.001)。
  • 左心室心肌组织蛋白质组学分析提示,ITGA1水平升高影响心脏纤维化相关通路,这些变化促进HFpEF的发生和进展。

临床怎么用

  • 作者认为,测量ITGA1有助促进风险分层和早期干预,以减轻糖尿病相关的不良心血管影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Type 2 diabetes mellitus is known to contribute to the development of heart failure with preserved ejection fraction (HFpEF). However, identifying HFpEF in individuals with type 2 diabetes early on is often challenging due to a limited array of biomarkers. This study aims to investigate specific biomarkers associated with the progression of HFpEF in individuals with type 2 diabetes, for the purpose of enabling early detection and more effective management strategies. METHODS: Blood samples were collected from individuals with type 2 diabetes, both with and without HFpEF, for proteomic analysis. Plasma integrin α1 (ITGA1) levels were measured and compared between the two groups. Participants were further categorised based on ITGA1 levels and underwent detailed transthoracic echocardiography at baseline and during a median follow-up period of 30 months. Multivariable linear and Cox regression analyses were conducted separately to assess the associations between plasma ITGA1 levels and changes in echocardiography indicators and re-hospitalisation risk. Additionally, proteomic data for the individuals' left ventricles, from ProteomeXchange database, were analysed to uncover mechanisms underlying the change in ITGA1 levels in HFpEF. RESULTS: Individuals with type 2 diabetes and HFpEF showed significantly higher plasma ITGA1 levels than the individuals with type 2 diabetes without HFpEF. These elevated ITGA1 levels were associated with left ventricular remodelling and impaired diastolic function. Furthermore, during a median follow-up of 30 months, multivariable analysis revealed that elevated ITGA1 levels independently correlated with deterioration of both diastolic and systolic cardiac functions. Additionally, higher baseline plasma ITGA1 levels independently predicted re-hospitalisation risk (HR 2.331 [95% CI 1.387, 3.917], p=0.001). Proteomic analysis of left ventricular myocardial tissue provided insights into the impact of increased ITGA1 levels on cardiac fibrosis-related pathways and the contribution made by these changes to the development and progression of HFpEF. CONCLUSIONS/INTERPRETATION: ITGA1 serves as a biomarker for monitoring cardiac structural and functional damage, can be used to accurately diagnose the presence of HFpEF, and can be used to predict potential deterioration in cardiac structure and function as well as re-hospitalisation for individuals with type 2 diabetes. Its measurement holds promise for facilitating risk stratification and early intervention to mitigate the adverse cardiovascular effects associated with diabetes. DATA AVAILABILITY: The proteomic data of left ventricular myocardial tissue from individuals with type 2 diabetes, encompassing both those with and without HFpEF, is available from the ProteomeXchange database at http://proteomecentral.proteomexchange.org .

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Su M, Hou Y, Cai S, et al. Elevated ITGA1 levels in type 2 diabetes: implications for cardiac function impairment. Diabetologia. 2024. PMID: 38413438. doi:10.1007/s00125-024-06109-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。